- Pharmaceutical companies
- Europe
- Portugal
- Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. in Portugal
E-mail: info@daiichi-sankyo.pt
Web: https://www.daiichi-sankyo.pt/
Address:
-
Daiichi Sankyo Portugal, Unipessoal Lda.
Tagus Park, Avenida Professor Doutor Cavaco Silva, Edifício Tecnologia IV, nº 81 a 83 2740-245 Porto Salvo
Phone: +351 21 423 2010
Other Daiichi Sankyo Co., Ltd.'s locations around the world
Clinical Trials sponsored by Daiichi Sankyo Co., Ltd.
-
Daiichi Sankyo Co., Ltd.RekryteringFast tumör | Metastatisk fast tumör | Avancerad cancerJapan, Förenta staterna, Kanada
-
Daiichi Sankyo Co., Ltd.Aktiv, inte rekryterandeTenosynovial jättecelltumörTaiwan, Kina
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAktiv, inte rekryterande
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAktiv, inte rekryterandeMelanomKorea, Republiken av, Kina
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Aktiv, inte rekryterandeIcke-småcellig lungcancer Metastaserande | Icke-småcellig lungcancer med mutation i epidermal tillväxtfaktorreceptorFörenta staterna, Spanien, Korea, Republiken av, Frankrike, Storbritannien, Taiwan, Australien, Japan, Kina, Nederländerna, Italien, Tyskland, Österrike, Belgien, Bulgarien, Singapore
-
Daiichi Sankyo Co., Ltd.Aktiv, inte rekryterandeVuxen T-cell leukemi/lymfomJapan
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Aktiv, inte rekryterandeBröstcancerKina, Förenta staterna, Spanien, Ungern, Israel, Korea, Republiken av, Taiwan, Belgien, Österrike, Ryska Federationen, Schweiz, Portugal, Frankrike, Kanada, Italien, Storbritannien, Grekland, Japan, Tyskland, Sverige
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.Aktiv, inte rekryterande
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Aktiv, inte rekryterandeBröstcancerFörenta staterna, Spanien, Israel, Italien, Korea, Republiken av, Belgien, Australien, Tjeckien, Japan, Brasilien, Frankrike, Storbritannien, Kalkon, Grekland, Tyskland
-
Daiichi Sankyo Co., Ltd.AvslutadMagcancerKorea, Republiken av, Hong Kong, Taiwan, Kina
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen. Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).